Academic Journals Database
Disseminating quality controlled scientific knowledge

Infliximab Treatment in Resistant Pyoderma Gangrenosum: A Case Report

Author(s): Yunus DURMAZ | Ayhan Bilgici | Erhan Erdem CİL | Ömer KURU

Journal: Türkiye Fiziksel Tip ve Rehabilitasyon Dergisi
ISSN 1302-0234

Volume: 58;
Issue: 4;
Start page: 332;
Date: 2012;
Original page

Keywords: Pyoderma gangrenosum | infliximab | anti-TNF

Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis consisting of nodules and pustules that ulcerate. Pyoderma gangrenosum is associated with autoimmune disorders such as inflammatory bowel disease, spondyloarthritis, and rheumatoid arthritis. In mild disease, therapy consists of local wound care and topical or intralesional corticosteroids. For more severe disease, systemic agents are necessary. Herein, we present the case of a patient with steroid resistant pyederma gangrenosum associated with ulcerative colitis and ankylosing spondylitis who responded well to infliximab, a tumor necrosis factor blocker. Biological agents (anti-TNF) may be alternative treatment options in patients with resistant PG. Turk J Phys Med Re­hab 2012;58:332-4.
Save time & money - Smart Internet Solutions      Why do you need a reservation system?